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Abstract
Background: Despite several effective treatment options available for prostate cancer, it remains
the second leading cause of cancer death in American men. Thus, there is a great need for new
treatments to improve outcomes. One such strategy is to eliminate cancer through the expression
of cytotoxic genes specifically in prostate cells by gene therapy vectored delivery. To prevent
systemic toxicity, tissue- and/or cancer-specific gene expression is required. However, the use of
tissue- or cancer-specific promoters to target transgene expression has been hampered by their
weak activity.
Results: To address this issue, we have developed a regulation strategy that includes feedback
amplification of gene expression along with a differentially suppressible tetracycline regulated
expression system (DiSTRES). By differentially suppressing expression of the tetracycline-regulated
transcriptional activator (tTA) and silencer (tTS) genes based on the cell origin, this leads to the
activation and silencing of the TRE promoter, respectively. In vitro transduction of LNCaP cells with
Ad/GFPDiSTRES lead to GFP expression levels that were over 30-fold higher than Ad/CMV-GFP.
Furthermore, Ad/FasL-GFPDiSTRES demonstrated cytotoxic effects in prostate cancer cells known
to be resistant to Fas-mediated apoptosis.
Conclusion:  Prostate-specific regulation from the DiSTRES system, therefore, serves as a
promising new regulation strategy for future applications in the field of cancer gene therapy and
gene therapy as a whole.
Background
While the prostate cancer death rate has been decreasing
steadily in the U.S. since the 1990s, prostate cancer
remains the second leading cause of cancer death in men,
with an estimated 27,050 deaths predicted to occur in
2007 [1]. When the disease is confined to the prostate, it
can be cured by radical prostatectomy or irradiation ther-
apy. However, there are no curative therapies for locally
advanced, recurrent, or metastatic diseases. There is, there-
fore, a need to investigate alternative treatment strategies
to improve these outcomes. One such approach is the use
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of cytotoxic gene therapy vectors directed against prostate
cancer cells.
Several prostate cancer gene therapy strategies have been
or are currently being evaluated in clinical trials [2]. These
treatments have been well tolerated and have shown some
indications of biological activity. In 2004 and 2005, the
Chinese State Food and Drug Administration (SFDA)
approved the first gene therapy-based products for cancer
treatment: Gendicine (Sibiono GeneTech Co.) and H101
(Sunway Biotech Co.) [3,4]. The effectiveness of these two
adenovirus-based products are quite encouraging for sim-
ilar vectors being developed in the US, Advexin (Introgen)
and ONYX-015 (Onyx Pharmaceuticals).
The ideal vector for prostate cancer gene therapy would be
one that is both prostate-specific yet still elicits highly
induced expression of the therapeutic gene. Previously, we
developed and characterized a novel gene therapy regula-
tion system known as the positive feedback loop with
prostate specificity, or PFLPS, regulation system [5]. This
system initiated a positive feedback loop of gene expres-
sion specifically in cells of prostate origin while retaining
prostate-specificity even at MOI as high as 1000 [5]. The
PFLPS system was developed by making specific modifica-
tions of the Tet-off regulation system (originally devel-
oped by Dr. Hermann Bujard [6]) to include the prostate-
specific ARR2PB promoter (originally developed by Dr.
Robert J. Matusik [7]).
While the PFLPS regulation system worked well for induc-
ing GFP expression, incorporation of the pro-apoptotic
FasL-GFP fusion into the PFLPS system gave only modest
levels of cytotoxicity (Woraratanadharm, unpublished).
In an attempt to improve the cytotoxicity of our vector, we
developed an alternative strategy for achieving amplified
prostate-specific transcriptional regulation. This system,
which we have named the differentially suppressible tetra-
cycline regulated expression system, or DiSTRES, was
incorporated into a replication-incompetent Ad vector
deleted in E1, E3, and E4 (except for E4orf6), and is simi-
lar to PFLPS, as it incorporates positive feedback loop
amplification of gene expression as a result of incorpora-
tion of the TRE-ARR2PB promoter. However, the DiSTRES
regulation strategy differs from PFLPS in that it investi-
gates an alternative mechanism for regulating gene expres-
sion by including additional transcriptional regulatory
elements to differentially suppress transgene expression
depending on the cell type transduced.
In this study, we describe the development and character-
ization of our new DiSTRES regulation system. The DiS-
TRES system demonstrated highly induced, prostate-
specific gene expression when incorporated into a com-
plex Ad vector. In the presence of dihydrotestosterone
(DHT), these levels could be induced to levels up to 30
times higher than that of the CMV promoter and up to 10
times higher than our non-specific tet-regulated control.
In addition, when FasL-GFP expression was mediated by
the DiSTRES system, this vector demonstrated prostate-
specific cytotoxicity, even in the FasL-resistant LNCaP cell
line. Prostate-specific regulation from the DiSTRES sys-
tem, therefore, serves as a promising new regulation strat-
egy for future applications in the field of cancer gene
therapy and gene therapy as a whole.
Results
Design of the Differentially Suppressible Tetracycline 
Regulated Expression System (DiSTRES)
The Tet-off system was originally designed by Hermann
Bujard's group [6]. In this system, the tetracycline-regu-
lated transcriptional activator protein (tTA) was devel-
oped to have binding affinity for a tandem repeat of DNA
sequences known collectively as the tetracycline-respon-
sive element (TRE). Binding of tTA to the TRE causes tran-
scriptional activation of downstream promoters. The
addition of tetracycline or its analog, doxycycline, to the
system causes the tTA to lose its affinity for the TRE, and
therefore, results in a loss of transcriptional activation.
Bujard's group also developed an opposing system, which
utilizes the tetracycline-regulated transcriptional silencer
protein (tTS) [8]. Like tTA, tTS binds to the TRE and loses
its affinity for the TRE in the presence of tetracycline or
doxycycline. Opposite from tTA, however, binding of tTS
to the TRE leads to transcriptional silencing (not activa-
tion) of downstream promoters. Therefore, differential
expression of tTA in certain contexts and tTS in other con-
texts can be utilized to either turn "on" or "off" a particu-
lar gene's expression, respectively.
Our first generation Tet-regulated, prostate-specific (PS/
TR) vector [9] was developed by a slight modification of
the Tet-off system in which the tTA was driven by the pros-
tate-specific ARR2PB promoter instead of by the CMV pro-
moter (see Fig. 1). This vector lacked the positive feedback
loop incorporated into both the PFLPS and DiSTRES vec-
tors. It also demonstrated a low level of detectable trans-
gene expression in non-prostate cells. We believed this to
be the result of a slight induction of the TRE promoter
even in the absence of tTA expression. To improve this sys-
tem, we developed the PFLPS system.
In the PFLPS regulation system, we cloned the TRE
upstream of the ARR2PB promoter to develop a prostate-
specific, tTA-inducible promoter known as the TRE-
ARR2PB promoter (see Fig. 1). Using the TRE-ARR2PB
promoter to drive the expression of both tTA and GFP led
to a positive feedback loop which was only activated in
prostate cells [5]. This activity was effective at inducingBMC Biotechnology 2007, 7:9 http://www.biomedcentral.com/1472-6750/7/9
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GFP expression, but FasL-GFP induction was somewhat
modest.
In order to amplify prostate-specific expression further,
we developed the novel DiSTRES regulation system. In
this system we added two transcriptional silencer pro-
teins, the tTS protein and the Lac repressor (LacR) protein,
to the positive feedback loop design in order to differen-
tially suppress gene expression depending upon the cell
type transduced. The conceptual difference between
PFLPS and DiSTRES is that in DiSTRES, the gene of inter-
est is driven by the original TRE promoter instead of the
prostate-specific ARR2PB-TRE promoter. From our previ-
ous experience with PS/TR, we found that the original TRE
promoter often has some low level activity even in the
absence of tTA expression. To counteract this activity, we
added the tTS suppressor to decrease background trans-
gene activation in non-target cells. However, in the setting
of a prostate cell, tTS is not induced due to negative regu-
lation from the LacR repressor (see Figs 1 and 2).
The design of the DiSTRES regulation system as cloned
into an Ad5 vector deleted in E1, E3, and E4 (except for
E4orf6) is depicted in Fig. 1. Control Ad vectors include
Structure of the Ad/GFPDiSTRES vector and controls Figure 1
Structure of the Ad/GFPDiSTRES vector and controls. All transgene cassettes were first cloned into pLAd and pRAd shut-
tle vectors as described in the Methods section. Vector genomes were then assembled in vitro, as described previously [30, 31]. 
The resulting rAd vectors are E1-deleted and have a deletion in the E3 region (E3 promoter is retained). They also lack all of 
the E4 ORFs, except orf6, which is expressed from the E4 promoter.BMC Biotechnology 2007, 7:9 http://www.biomedcentral.com/1472-6750/7/9
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Mechanism of action of the Ad/GFPDiSTRES vector Figure 2
Mechanism of action of the Ad/GFPDiSTRES vector. Mechanism of action of the Ad/GFPDiSTRES vector when transduced into a 
prostate cell (top panel). We hypothesize that the following sequence of events would occur in the prostate cell: (1) Both the tTA 
and the LacI genes would be induced, as a result of activation of the prostate specific TRE-ARR2PB promoters that drive the 
expressions of these genes; (2) Expression of tTA would then lead to transcriptional activation of the gene of interest (e.g., 
GFP), through binding of tTA to the TRE promoter; (3) The tTA protein would also bind to the TRE within its own TRE-
ARR2PB promoter, thereby activating further transcription of itself and therefore establishing a positive feedback amplification 
loop of tTA expression; (4) Meanwhile, the LacR protein would bind to the LacR-responsive promoter of the tTS gene, thereby 
leading to suppression of tTS gene transcription; and (5) Finally, the tTA-driven amplification loop would lead to further expres-
sion of both the gene of interest and the LacR (and subsequently further repress the tTS). Mechanism of action in non-prostate 
cells (bottom panel). In the non-prostate cell, we propose the following scenario: (1) Because the TRE-ARR2PB promoter is 
prostate-specific, neither the tTA nor the LacR proteins would be expressed; (2) In the absence of the LacR protein, the LacR-
responsive promoter acts essentially like its constitutively active parental promoter (the CMV promoter). As a result, the tTS 
gene is now actively transcribed; and (3) Expression of the tTS protein would then lead to the transcriptional silencing of all 
TRE-regulated promoters, and therefore, the gene of interest (GFP), tTA and LacR would all be suppressed upon binding of 
the tTS to the TRE's within their respective promoters. Note: Tetracycline and/or doxycycline are not added to this system. 
Adding these drugs would act to negate the effects of the differential regulation of tTA versus tTS. The result would be basal 
expression of GFP in both cell types, and therefore, a loss in prostate-specificity.BMC Biotechnology 2007, 7:9 http://www.biomedcentral.com/1472-6750/7/9
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Ad/GFPTET, which expresses GFP under the control of the
traditional tet-off regulatory system, Ad/CMV-GFP, which
expresses GFP under the control of the strong, constitu-
tively active CMV promoter, and Ad/C.LacZ, which
expresses β-galactosidase under the control of the CMV
promoter. The designs of our earlier generation PS/TR and
PFLPS vectors are also shown.
In the DiSTRES vector, three transgene cassettes were
cloned into the right-end of the genome, which includes
the following: (1) TRE-ARR2PB promoter driving Lac
repressor (LacI) gene expression, cloned in reverse orien-
tation, (2) ARR2PB promoter driving tTA  expression,
cloned just downstream of the TRE-ARR2PB.LacI cassette
such that the TRE has bi-directional activity on both the
LacI and tTA genes, and (3) original TRE promoter con-
trolling GFP expression, cloned downstream of the
ARR2PB.tTA cassette (see Fig. 1). In addition, a transgene
cassette containing a newly developed LacR-responsive
promoter (see Methods) was cloned into the left-end of
the genome and controlled tTS gene expression (see Fig.
1).
The cloning capacity of our E1/E3/E4(except orf6)-deleted
Ad vector is approximately 7.5 kb. Therefore, several stra-
tegic cloning measures had to be taken in order to con-
serve sufficient space to include all four transgene
cassettes into a single complex adenovirus vector (see
Methods). In addition, special consideration was made in
the construction of this complex rAd vector based upon
our previous findings regarding interference from the E1a
enhancer. Because we previously had found that the basal
activity of both the TRE and the ARR2PB promoters were
significantly affected by interference from the E1a
enhancer [10], we designed the Ad/GFPDiSTRES vector so
that all TRE and TRE-ARR2PB promoters were away from
the E1 region by placing them near the right ITR (Fig. 1).
Meanwhile, the transgene cassette containing the LacR-
responsive promoter driving tTS expression was cloned
near the left ITR (Fig. 1). The theoretical mechanism of
action of the DiSTRES regulation system is diagrammed in
Fig. 2.
Levels of prostate-specific expression from Ad-delivered 
DiSTRES are greater than that induced by either the CMV 
promoter or tet-regulated controls
In order to determine the prostate-specificity of the Ad/
GFPDiSTRES vector, two prostate cancer cell lines, LNCaP
and PC3/AR, and two non-prostate cell lines, HeLa and
U251MG, were chosen for in vitro analysis. Since the
ARR2PB promoter is known to be inducible by androgen
(e.g., dihydrotestosterone; DHT) [7], the LNCaP cell line
was chosen specifically because it is one of the few pros-
tate cancer cell lines available that express functional
androgen receptor (AR). The PC-3 cell line is known to be
AR negative, and therefore, an AR stable transfectant PC-3
cell line (PC3/AR) was chosen [11] for the Ad/GFPDiSTRES
characterization studies. In order to directly compare vec-
tor activity in prostate versus non-prostate cells, all cell
types were infected in the presence of DHT, even though
DHT would not likely be present under physiological tis-
sues.
For in vitro analysis, both prostate and non-prostate cell
lines were infected with Ad/GFPDiSTRES vector and controls
(Fig. 3). Due to differing transduction efficiencies among
cell lines, each cell type was infected at an optimized MOI,
based on pilot dose response studies conducted with the
Ad/GFPTET vector. Data are represented as fold GFP expres-
sion, setting infection with the Ad/CMV-GFP control vec-
tor at 1. As demonstrated in Fig. 3, Ad/GFPDiSTRES vector
induced high levels of GFP expression in the prostate can-
cer cell lines without a loss in prostate specificity. In PC3/
AR cells, the Ad/GFPDiSTRES vector induced GFP expression
to levels similar to the non-specific, constitutively active
Ad/CMV-GFP control. Remarkably, GFP induction by the
Ad/GFPDiSTRES vector in LNCaP cells was not only signifi-
cantly higher than that seen with Ad/CMV-GFP  (p =
0.043) but also significantly amplified, even in compari-
son to the Ad/GFPTET vector (p = 0.038). In fact, the activ-
ity from Ad/GFPDiSTRES was over 30-fold higher than Ad/
CMV-GFP  and over 10-fold higher than the highly
induced tet-regulated Ad/GFPTET vector, when transduced
in LNCaP cells. Meanwhile, the levels of GFP expression
in the HeLa and U251MG cells were similar to back-
ground, with a low level of GFP expression seen in HeLa
cells.
The Ad/GFPDiSTRES vector demonstrates improved 
prostate-specific GFP induction compared to the earlier 
generation, Ad/GFPPS/TR and Ad/GFPPFLPS vectors
We wanted to determine whether the DiSTRES system had
improved upon our earlier generation designs, the PS/TR
and PFLPS systems. In order to conduct a comparative
analysis of these three prostate-specific regulation sys-
tems, we infected LNCaP and U251MG cells in parallel
with Ad/GFPPS/TR, Ad/GFPPFLPS, Ad/GFPDiSTRES, Ad/
GFPTET, or Ad/C.LacZ and assayed for GFP expression (Fig.
4). As demonstrated in Fig. 4, the activity of the Ad/GFPPS/
TR vector (which lacks the positive feedback loop) was less
than that induced by either Ad/GFPPFLPS or Ad/GFPDiSTRES
in LNCaP cells at all MOI's tested. Overall, the Ad/GFPDiS-
TRES vector demonstrated the highest levels of prostate-spe-
cific GFP expression at all MOI's tested. In addition, the
Ad/GFPPS/TR  vector demonstrated more non-specific
expression in U251MG than either Ad/GFPPFLPS or Ad/
GFPDiSTRES, except at MOI 1000, where the Ad/GFPDiSTRES
vector loses some of its specificity. Finally, Fig. 4 visually
demonstrates the difference in GFP induction and specif-BMC Biotechnology 2007, 7:9 http://www.biomedcentral.com/1472-6750/7/9
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icity of Ad/GFPDiSTRES versus Ad/GFPTET in LNCaP and
U251MG cells at MOI 100.
DiSTRES-mediated FasL-GFP cytotoxicity is prostate-
specific
In order to characterize the DiSTRES regulation system in
the context of a prostate cancer therapeutic, we first sub-
cloned the FasL-GFP fusion gene in the place of the GFP
gene within Ad/GFPDiSTRES, resulting in the Ad/FasL-GFP-
DiSTRES vector. We then infected the same panel of prostate
and non-prostate cell lines described in Fig. 3 with Ad/
FasL-GFPDiSTRES vector and controls and assayed for result-
ant cell viability (see Fig. 5). Since each cell type showed
varying sensitivities to adenovirus-delivered FasL-GFP, we
infected each cell type at MOI values determined during
pilot studies to induce maximal cytotoxicity in response
to Ad/FasL-GFPTET control.
The cytotoxicity of all of the prostate-specific vectors was
prostate-specific, as there was increased cell viability in the
U251MG and HeLa cells when compared to the Ad/FasL-
GFPTET control. In LNCaP, cell viability in Ad/FasL-GFPDiS-
TRES-transduced cells was greatly reduced although not to
the same degree as our positive control for apoptosis, Ad/
FasL-GFPTET. In PC3AR, similar levels of cell viability were
seen among the three prostate-specific vectors.
In comparison to the PS/TR and PFLPS vectors, the DiS-
TRES vector demonstrated the highest level of cytotoxicity
in LNCaP cells. However, the cytotoxic activity of Ad/FasL-
GFPDiSTRES compared to mock infection was not statisti-
cally significant. Although the cell viability studies did not
reveal a statistical difference between Ad/FasL-GFPDiSTRES
and control, both prostate cancer cell types did demon-
strate the typical cell-rounding morphology as a result of
Ad/FasL-GFPDiSTRES infection (Fig. 6). However, U251MG
seemed to be somewhat affected by Ad/FasL-GFPDiSTRES
infection, as well.
Discussion
A wide range of gene therapy vector approaches is being
investigated as potential cancer therapeutics including
manipulation of cell cycle control, apoptosis strategies,
suicide gene therapy, tumor-selective replicating virus vec-
tors, angiogenesis therapy and immunotherapy. Recent
successes in cancer gene therapy include the approvals of
the Ad/p53 vector known as Gendicine from SiBiono
GeneTech Co. and the oncolytic Ad vector known as H101
Comparison of DiSTRES- and CMV-mediated gene expression Figure 3
Comparison of DiSTRES- and CMV-mediated gene expression. LNCaP, PC3AR, HeLa and U251MG cells were 
seeded at 1.25 × 104 cells/well in 96-well plates and infected with complex Ad vectors at MOI 30, 200, 200, and 50, respec-
tively, in the presence 30 nM DHT. 2 days post-infection, cell lysates were assayed for GFP fluorescence. Infection with Ad/
C.LacZ served as a negative control infection. Results are displayed as fold expression, setting GFP fluorescence from Ad/
CMV.GFP infection at 1 for each cell line. Due to differing transduction efficiencies among cell lines, each cell type was infected 
at an optimized MOI, based on pilot dose response studies conducted with the Ad/GFPTET vector. MOI values were based on 
IU/ml. *p < 0.05 compared to Ad/CMV.GFP. †p < 0.05 compared to Ad/GFPTET.BMC Biotechnology 2007, 7:9 http://www.biomedcentral.com/1472-6750/7/9
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Ad/GFPDiSTRES demonstrates specificity for prostate cells, decreased activity in non-prostate control cells, and improves upon  earlier vector designs Figure 4
Ad/GFPDiSTRES demonstrates specificity for prostate cells, decreased activity in non-prostate control cells, and 
improves upon earlier vector designs. GFP fluorescence of (a) LNCaP cells and (b) U251MG cells. LNCaP and U251MG 
cells were seeded at 1.25 × 104 cells/well of a 96-well plate and infected with Ad/GFPTET, Ad/GFPPS/TR, Ad/GFPPFLPS, Ad/GFPDiS-
TRES, or Ad/C.LacZ (negative control) in the presence of 30 nM DHT at MOI 1, 10, 100, or 1000. 2 days post-infection, cell 
lysates were assayed for GFP fluorescence. RFU: relative fluorescence units. MOI values were based on IU/ml.BMC Biotechnology 2007, 7:9 http://www.biomedcentral.com/1472-6750/7/9
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from Sunway Biotech Co. for clinical use in China [3,4].
The activity of both of these adenovirus-based vectors
takes advantage of the fact that over 50% of all cancers
have mutations in p53. Additionally, evidence from
Onyx's ONYX-015 and Sunway's H101 vectors appear to
indicate that these oncolytic vectors also have activity in
non-p53 mutant cancer cells as well [3].
When designing gene therapy vectors for the treatment of
cancer, along with selection of therapeutic transgene, an
equally important aspect to take under consideration is
how to target gene expression. This is particularly impor-
tant considering that the two initial phases of clinical
characterization (Phase I and II clinical trials) focus on
safety. The cancer gene therapy vector most likely to dem-
onstrate a significant clinical result will be one that initi-
ates a large therapeutic index (i.e., high potency against
malignant cells), while keeping toxicity to normal tissues
at a minimum. The use of an amplified feedback loop
strategy to tightly regulate yet highly induce gene expres-
sion may be key to the development of additional cancer
therapeutic vectors.
Ad/FasL-GFPDiSTRES demonstrates preferential cytotoxicity in prostate cells Figure 5
Ad/FasL-GFPDiSTRES demonstrates preferential cytotoxicity in prostate cells. LNCaP, PC3AR, U251MG, and HeLa 
cells were seeded at 1.25 × 104 cells/well in a 96-well plate and infected with Ad/FasL-GFPTET, Ad/FasL-GFPPS/TR, Ad/FasL-GFPP-
FLPS, Ad/FasL-GFPDiSTRES, or 1× HBS (mock) in the presence of 30 nM DHT. LNCaP, PC3AR, U251MG, and HeLa were infected 
at MOI 10, 5, 5, and 2.5, respectively. Three days post-infection, cells were fixed with methanol and then assayed for cytotox-
icity using crystal violet assay. Since each cell type showed varying sensitivities to adenovirus-delivered FasL-GFP, we infected 
each cell type at MOI values determined during pilot studies to induce maximal cytotoxicity in response to Ad/FasL-GFPTET con-
trol. Percent viability was calculated by dividing the mean absorbance of each sample by the mean absorbance of 1× HBS mock 
infection for each cell line and then multiplying by 100%. MOI values were based on pfu/ml. Horizontal line delineates 100% via-
bility.BMC Biotechnology 2007, 7:9 http://www.biomedcentral.com/1472-6750/7/9
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In this study, we have constructed and characterized a
novel transcriptional regulation system that incorporates
both an amplification feedback loop, as well as two tissue-
selective repressor elements, which differentially suppress
specific transcriptional events, depending upon the cell
type transduced. This differentially suppressible tetracy-
cline regulated expression system (DiSTRES) demon-
strated prostate-specific transgene induction, as the Ad/
GFPDiSTRES vector was found to induce GFP expression lev-
els in PC3/AR cells to levels similar to that of the CMV
promoter, a promoter which is well-recognized as a
strong, constitutively active promoter of non-specific gene
expression. Moreover, the Ad/GFPDiSTRES vector induced
GFP expression levels in LNCaP cells to levels that signifi-
cantly exceeded those of both the CMV promoter as well
as the tet-regulated system. This induction by Ad/GFPDiS-
TRES was approximately 30 times the activity of Ad/CMV-
GFP  and approximately 10 times the activity of Ad/
GFPTET. Additionally, the Ad/GFPDiSTRES vector retained
specificity in the two non-prostate cell line controls, HeLa
and U251MG. Levels of GFP expression from the Ad/GFP-
DiSTRES vector, upon transduction of these non-prostate cell
lines, were similar or slightly higher than background.
Finally, although LNCaP cells are known to be resistant to
FasL-mediated apoptosis, the Ad/FasL-GFPDiSTRES vector
demonstrated cytotoxic effects in LNCaP and somewhat
modest effects in PC3AR cells. This overcoming of FasL
resistance was seen previously with our tet-regulated Ad/
FasL-GFPTET vector [12], and we believe it is due to an
overexpression of FasL-GFP overcoming a certain thresh-
old in these resistant cells. Once the cells are saturated
Ad/FasL-GFPDiSTRES demonstrates prostate-specific cytotoxicity as indicated by rounded morphology of prostate cancer cells Figure 6
Ad/FasL-GFPDiSTRES demonstrates prostate-specific cytotoxicity as indicated by rounded morphology of pros-
tate cancer cells. LNCaP, PC3AR, and U251MG cells were seeded at and infected as described in Fig. 5. LNCaP, PC3AR, and 
U251MG were infected at MOI 10, 5, and 5, respectively. Two days post-infection, cells were visualized using Axiovert-25 flu-
orescent microscope with FITC filter set and photos taken with Pixera digital camera at 100× magnification. Photos on the left 
were taken under UV light. Photos on the right were taken under bright field setting. MOI values are based on pfu/ml.BMC Biotechnology 2007, 7:9 http://www.biomedcentral.com/1472-6750/7/9
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with FasL-GFP, the cell then appears to become suscepti-
ble to the FasL-mediated apoptosis.
A two-step transcriptional amplification (TSTA) system
has been described which utilizes a Gal4-VP16 fusion pro-
tein instead of tTA for amplification of gene expression
[13-17] and is similar to our previous PS/TR system [9]. In
transfection experiments, Zhang et al. demonstrates a 10-
fold increase in prostate-specific luciferase expression in
LNCaP, compared to CMV [17]. In another report, Block
et al. claims an amplification of up to 590-fold of luci-
ferase expression in SKCO1 cells compared to CMV [13].
Similar results have not been repeated by other groups
using the TSTA system. The specificity of Block et al's vec-
tor, however, was greatly compromised as a result. In their
negative control cell line, HepG2, their Ad.Mucbin-luc vec-
tor demonstrated 7-fold higher gene expression than CMV
at MOI 1. The authors do not explain the reasoning for
this very high background activity in non-target cells [13].
Such increased expression in non-target cells could poten-
tially be mitigated utilizing a system similar to DiSTRES.
However, it is difficult to compare the two systems since
many papers do not describe the activity of the TSTA in
non-target cells. Further study will need to be conducted
to truly compare the two systems.
The DiSTRES transcriptional regulation system has three
characteristics that separate it from other regulation sys-
tems published in the literature: (1) differential expres-
sion of two transcriptional repressor proteins (tTS or
LacR) depending on the cell type transduced; (2) incorpo-
ration of a positive feedback amplification loop of pros-
tate specific gene expression; and (3) the cloning of the
entire system into a single complex recombinant Ad vec-
tor, thus preventing the need for co-infection with two or
more separate Ad vectors. In fact, most Ad vectors pub-
lished in the literature (gutless Ad vectors included) con-
tain only a single transgene cassette. This, therefore,
makes the progressiveness of the Ad/GFPDiSTRES and Ad/
FasL-GFPDiSTRES vectors rather uncommon as both of these
vectors each contained four expression cassettes.
Application of the DiSTRES regulation system is not
restricted to only the gene therapy treatment of prostate
cancers. Its complex transcriptional regulation concept
could be transferred to other tissue types by simply incor-
porating different tissue-specific promoters, thereby
expanding its potential utility to include gene therapy of
other cancers and molecular genetic applications other
than cancer, such as the gene therapy treatment of genetic
disorders, development of gene-based vaccines expressing
immunogenic bacterial or viral antigens, and develop-
ment of new transgenic mouse models that require highly
induced, organ-restricted expression of a particular gene
of interest. Finally, the effective transcriptional regulation
afforded by DiSTRES could be combined with current
methods of transductional regulation including manipu-
lation of Ad fiber knob [18-24] and use of bi-specific anti-
bodies [25-29] to further improve the targeting of gene
therapy vectors to specific cell types and therefore increase
the specificity and the safety of the vectors.
Conclusion
We have developed and characterized a novel transcrip-
tional regulatory system that demonstrates highly
induced, prostate-specific expression that retains its tis-
sue-specificity. Such a regulation system could be poten-
tially modified to include tissue- or cancer-specific
promoters in the place of the ARR2PB promoter as well as
any desired therapeutic transgene and thus is ideal for sev-
eral molecular genetic and gene therapeutic applications
that require highly induced, organ-restricted expression of
a particular gene of interest. This transcriptional regula-
tion can also be combined with transductional regulation
systems to increase the specificity and the safety of current
gene therapy vectors. The DiSTRES regulation system,
therefore, serves as a promising new approach for the tran-
scriptional regulation of therapeutic genes for future
molecular genetic and therapeutic applications.
Methods
Cell lines
HEK293 (human embryonic kidney) and LNCaP (pros-
tate cancer) cells were obtained from American Type Cul-
ture Collection (ATCC; Manassas, VA). U343MG and
U251MG (brain tumor) cell lines were obtained from the
Brain Tumor Research Center Tissue Bank (Dept. of Neu-
rological Surgery, UCSF, San Francisco, CA). PC3/AR (the
human prostate cancer cell line, PC-3, stably transfected
with human androgen receptor cDNA) was generously
provided by Kerry L. Burnstein. All cell lines were main-
tained in media supplemented with 10% cosmic calf
serum (CCS; HyClone, Logan, UT), with HEK293 being
maintained in DMEM, LNCaP being maintained in RPMI,
PC3/AR being maintained in RPMI containing 350 μg/ml
active G418, and U343MG and U251MG being main-
tained in MEM.
Construction of plasmids vectors
The pUHD 10-3 (containing the TRE promoter), the
pUHD 15-1 (containing the tTA gene), and the pUHS 6-1
(containing the tTS gene) plasmids were generously pro-
vided by Hermann Bujard. The ARR2PB (0.45 kb) pro-
moter was developed in the laboratory of Robert J.
Matusik, who contributed the pARR2PB.PolI.TRZ-SK vec-
tor. Construction of pLAd-CMV, pLAd-mcs and pRAd-
T.GFP vectors has been described previously [12].
For construction of the DiSTRES vectors, first, the tTA gene
and BGH polyA were excised as a single fragment fromBMC Biotechnology 2007, 7:9 http://www.biomedcentral.com/1472-6750/7/9
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pUHD 10-3.B (a modified version of pUHD 10-3 which
includes a polyA from BGH in place of the original SV40
polyA) and subcloned in place of the SEAP gene within
the pLAd(2Pb.SP)r plasmid (described previously) [10],
resulting in the pLAd(2Pb.tTA.B)r  vector. Next, the
ARR2PB.tTA.B cassette from pLAd(2Pb.tTA.B)r was sub-
cloned upstream of the TRE.GFP cassette of pRAd2T.GFP.B
to obtain the pRAd2(2Pb.tTA.B)B(T.GFP.B) plasmid.
Next, the LacI gene was PCR amplified from the pCMV-
LacI plasmid (Stratagene) and then subcloned in the place
of the GFP gene within the pRAd2T2Pb.GFP.B plasmid
(described previously) [5], resulting in the
pRAd2T2Pb.LacI.B plasmid. Finally, the T2Pb.LacI cassette
was subcloned in reverse orientation upstream of the
ARR2PB.tTA  cassette within
pRAd2(2Pb.tTA.B)B(T.GFP.B), leading to construction of
the pRAd2(T2Pb.LacI)r(2Pb.tTA.B)B(T.GFP.B) right-end
shuttle plasmid of DiSTRES. By placing the T2Pb.LacI cas-
sette in reverse and upstream of he ARR2PB.tTA cassette,
this resulted in both the LacI and the tTA genes sharing a
TRE, thus conserving on much needed space, as well as
placing both genes under the control of TRE-ARR2PB pro-
moters.
The LacR-responsive promoter was developed by PCR-
amplifying the CMV promoter using oligos containing lac
operator (oi) sequences to modify the CMV promoter.
These oligos were designed to introduce a single lac oper-
ator near the 5' end of CMV as well as two lac operators
flanking the TATA box near the 3' end of the promoter.
The oligo sequences, 5'-TTTTTTTTTACTAGTGGAATTGT-
GAGCG CTCACAATTCCACATTAATAGTAATCAATTACG-
GGGTCATTAG-3' forward; and 5'-
TTTTTTTTTGGATCCTGTGGAATTGTGAGCGCTCACAAT
TCCACATCGAAATTCCGCGGACCGGTCGCCACCAT-
GGTGAGCAAGGGCGAGGA-3' reverse, were used to con-
struct the LacR-responsive promoter, using pcDNA3.1
(Invitrogen) as a template. The LacR-responsive promoter
PCR fragment was then cloned in the place of the CMV
promoter within the pUHS 6-1 plasmid to yield the pUHS
Coi2.tTS.S plasmid. Finally, the Coi2.tTS cassette was sub-
cloned into the pLAd-CMV plasmid in place of the CMV
promoter, resulting in the pLAd.Coi2.tTS left-end Ad shut-
tle plasmid vector.
It should be noted that the cloning capacity of our E1/E3/
E4(except orf6)-deleted Ad5 vector is approximately 7.5
kb and that the total size of the DiSTRES regulation system
just fits or slightly exceeds this value (~7.4 kb with GFP;
~8.16 kb with FasL-GFP). Therefore, in order to conserve
on space, both the tTS and the LacI genes were cloned into
their respective shuttle plasmids without polyadenylation
signals. PolyA sites were not required for these two partic-
ular transgene cassettes due to their orientations in rela-
tion to the deleted Ad genes within the Ad vector genome.
The polyA sites for the E1b and E4 genes can be utilized
for the polyadenylation of the tTS  and the LacI genes,
respectively.
Construction of recombinant adenoviral vectors
Construction of Ad/C.LacZ  and Ad/GFPTET  has been
described previously [12]. The
pRAd2(T2Pb.LacI)r(2Pb.tTA.B)B (T.GFP.B) plasmid was
digested with SwaI and SpeI while the pLAd.Coi2.tTS plas-
mid was digested with SwaI and AvrII. The digested
pLAd.Coi2.tTS  and
pRAd2(T2Pb.LacI)r(2Pb.tTA.B)B(T.GFP.B) fragments were
gel-purified and then ligated to a gel-purified Ad5 genome
backbone (Ad5sub360SR) digested on both ends with
XbaI. All Ad vectors are based on Ad5sub360SR, which
contains deletions in E3 and all E4 ORFs with the excep-
tion of ORF6. The Ad/FasL-GFPDiSTRES vector genome was
constructed in the same way as described for Ad/GFPDiS-
TRES, using a pRAd shuttle vector containing FasL-GFP sub-
cloned in the place of GFP.
Propagation of recombinant adenovirus vectors
All vectors were propagated in HEK293 cells, using stand-
ard procedures [12,30,31]. Briefly, HEK293 cells were
transfected with the complex Ad vector genome ligation
mixture using Fugene 6 transfection reagent (Roche, Indi-
anapolis, IN) following manufacturer's instructions.
Transfected cells were maintained until adenovirus-
related cytopathic effects (CPE) were observed (typically
7–14 days post-transfection), at which point the cells were
collected. Vector propagation and amplification was then
achieved by standard techniques. Briefly, adenoviral
lysates from twenty-four 150 mm plates were banded
twice on CsCl gradients and desalted twice with a PD-10
size exclusion column (Amersham Scientific, Piscataway,
NJ) into HEPES buffered saline (HBS; 21 mM HEPES, 140
mM NaCl, 5 mM KCl, 0.75 mM Na2HPO4·2H2O, and
0.1% (w/v) dextrose; adjust pH with NaOH to 7.5; and fil-
ter sterilize) containing 5% glycerol, and stored at -70°C.
Titering of recombinant adenovirus vector by infectious 
units
All vectors were titrated on HEK293 cells infected in serial
dilution on triplicate columns of 96-well plates for either
GFP fluorescence or X-gal staining. GFP fluorescence was
monitored with Axiovert-25 fluorescent microscope (Carl
Zeiss, Germany) and FITC excitation/emission filter set
(Chroma Technology Corp, Rockingham, VT) two days
post-infection. Cells infected with Ad/C.LacZ were fixed
two days post-infection with fixative solution (2% formal-
dehyde, 0.05% glutaraldehyde in 1× PBS) for 5 minutes at
room temperature and then stained overnight at 37°C in
X-gal solution (1 mg/ml X-gal (5-Bromo-4-chloro-3-
indolyl-β-D-galactopyranoside), 5 mM potassium ferricy-
anide, 5 mM potassium ferrocyanide, 2 mM MgCl2 in 1×BMC Biotechnology 2007, 7:9 http://www.biomedcentral.com/1472-6750/7/9
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PBS). The resulting titers were scored as infectious units
(IU) per ml.
Titering of recombinant adenovirus vector by particle 
forming units
All vectors were titrated on HEK293 cells infected in serial
dilution on duplicate wells of 12-well plates. The day
prior to infection, HEK293 cells were seeded with 2 × 105
cells/ml seeding density at 1 ml/well. 4 to 16 hrs post-
infection, cells were overlaid with 1 ml/well of 0.4% agar
(w/v) in DMEM/2% CCS and incubated at 37°C for 5–7
days until indications of CPE were observed. Cells were
fixed with 7% formaldehyde (v/v in dH2O) solution at
room temperature for 1 hr. Formaldehyde was aspirated
from wells, and agar plugs were carefully removed. Fixed
cells were stained for 10 min at room temperature with
0.2% crystal violet (w/v in dH2O). Plaques were visual-
ized using a standard light box. The resulting titers were
scored as plaque forming units (pfu) per ml. In compari-
son to IU titers, pfu titers were approximately 2 logs lower.
For example, the Ad/C.LacZ vector titer was 2.02 × 1011
IU/ml in infectious units and was 2.40 × 109 pfu/ml in
particle-forming units.
In vitro infections
1.25 × 104 cells/well were seeded in 96-well plates. Seeded
cells were infected 3 hours post-seeding at varying multi-
plicities of infections (MOI), depending on the cell line.
MOI calculations were based on cell numbers at the time
of seeding and on Ad vector titers based on IU/ml and
pfu/ml, for GFP infections and FasL-GFP infections,
respectively. In order to directly compare vector activity in
prostate versus non-prostate cells, all cell types were
infected in the presence of DHT, even though DHT would
not likely be present under physiological conditions in
non-prostate tissues.
Quantification of GFP expression
GFP fluorescence in cells was visualized 48 hours post-
transduction using Axiovert-25 fluorescent microscope
with FITC filter set. For quantitative analysis of GFP activ-
ity, cells were lysed with 0.5% Triton x-100 in 1× PBS. Cell
lysates were transferred to 96-well black microtiter plates
(BMG Labtechnologies, Offenburg, Germany) and rela-
tive GFP fluorescence was measured using FLUOstar™
dual fluorescence/absorbance plate reader (BMG Labtech-
nologies) at excitation 485 nm and emission 520 nm.
Quantification of cell viability
Two or three days post-infection, cells were fixed in 100%
methanol overnight at -20°C. Cell monolayers were
stained with 0.2% crystal violet for 2 min at room temper-
ature. Plates were washed twice with dH2O and then
destained with 50 μl/well of destain solution (30% meth-
anol, 10% acetic acid in dH2O) for wells of 96-well plate.
Plates were assayed for absorbance at 620 nm. Percent via-
bility was calculated by dividing the mean absorbance of
each sample by the mean absorbance of 1× HBS mock
infection and then multiplying by 100%.
Statistical analysis
All assays were performed in duplicate and the results
were expressed as the mean ± standard error of the mean
(SEM). Statistical analysis was determined using a two-
sample t-test.
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